Conditions We Review

Knee osteoarthritis is the most-studied application in regenerative medicine.

Of everything discussed under the regenerative umbrella, intra-articular cell therapy for knee osteoarthritis has the deepest published evidence base. Multiple meta-analyses of randomized controlled trials have now pooled results across hundreds of patients.

Here is what those analyses found, what determines whether you are in the population they studied, and what to ask before you decide.

Aurenza does not claim that regenerative medicine treats or reverses orthopedic or joint conditions.

Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.

View Other Conditions

Research

What the Research Shows

Knee osteoarthritis is the most-studied application in regenerative medicine, full stop. Enough randomized controlled trials exist that researchers now pool them, and the pooled numbers are public and checkable.

A 2025 systematic review and meta-analysis in Stem Cell Research and Therapy found MSC injection significantly improved WOMAC scores at 6 months and 12 months, along with pain and knee outcome scores at both timepoints, with no significant difference in adverse events versus controls, and its subgroup analysis found adipose-derived sources and higher doses more effective. A 2025 dose-focused meta-analysis in the Journal of Orthopaedic Surgery and Research pooled six randomized trials covering 300 patients and found a WOMAC effect size of -1.35 at 12 months, a moderate to large treatment effect, with the full open-access analysis identifying a relationship between cell dose and outcome.

The direction holds across independent teams. A 2024 meta-analysis of 18 randomized controlled trials in Frontiers in Endocrinology found MSCs superior to placebo for both pain relief and functional improvement at 12 months with no significant difference in treatment-related adverse events, consistent with a 2018 pooled analysis in npj Regenerative Medicine and a 2021 meta-analysis in the Journal of Orthopaedic Surgery and Research.

Research

The Honest Line

Now the counterweight, in the same font. The Cochrane review of stem cell injections for knee osteoarthritis found treatment produced about a 1.2-point greater pain reduction on a 0-to-10 scale and roughly a 14-point greater functional improvement on a 0-to-100 scale versus placebo: real differences, and modest ones. A 2025 meta-analysis in Frontiers in Medicine went further and estimated that at six months roughly 63% of the pain reduction patients experience comes from contextual, placebo-related factors, with the cells adding a modest increment on top, at low certainty of evidence. Both things are true at once: the trials show real, statistically significant improvement, and no study shows a guarantee it works every time, or that it will work for you. The trials also studied specific grades of degeneration, generally earlier to moderate; nothing supports rebuilding cartilage in an advanced bone-on-bone joint or substituting for a replacement that is genuinely indicated.

Why This Is Exactly Where a Candidacy Review Comes In

The same procedure can be performed on a grade 2 knee and a grade 4 knee for the same invoice, with completely different odds of being appropriate. Grading your joint on current imaging is the step that decides whether any of the research above applies to you. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.

Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.

View Other Conditions

What Your Candidacy Review Covers

Current imaging, to grade the joint accurately rather than assume.

Whether your symptoms are biological or mechanical, since locking, catching, and instability point toward structural problems the research does not address.

Your diagnosis and prior procedures, including how previous injections responded.

Your activity goals, assessed honestly against what your joint structure will support.

Your bloodwork and records, since metabolic health and inflammatory markers affect the joint environment.

Physician panel review follows, with specialist input where needed.

What to Ask Any Provider

How are you grading my joint, on what imaging, and how recent? Does my grade match the patients in the trials you are citing? What is being administered, from what source, at what dose and verified cell count? The research suggests dose and source matter. What are yours and why? What would make me a poor candidate?

The Honest Limits

Individual results cannot be predicted or guaranteed. These applications are not FDA approved for these conditions, and the procedure takes place in Mexico under COFEPRIS regulation. Continue with your existing providers, and seek orthopedic evaluation for instability, locking, or sudden loss of function.

Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.

Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.

View Other Conditions